Personality predictors of antiaggressive response to fluoxetine: inverse association with neuroticism and harm avoidance.
Personality predictors of antiaggressive response to fluoxetine: inverse association with neuroticism and harm avoidance.
复制标题
氟西汀抗攻击反应的人格预测因子：与神经质和避免伤害呈负相关。
DOI：
10.1097/yic.0b013e32834978ac
复制
发表时间：
2011
影响因子：
2.6
通讯作者：
Coccaro,EmilF
中科院分区：
文献类型：
--
作者：
Phan,KLuan;Lee,Royce;Coccaro,EmilF
尽管选择性5-羟色胺再摄取抑制剂（SSRI）通常可以有效减少间歇性爆发性障碍患者的冲动攻击性，但尽管有足够的剂量和治疗持续时间，很大一部分间歇性爆发性障碍患者仍无法达到完全缓解。气质，特别是那些与消极情绪（神经质、避免伤害）相关的气质可以预测对 SSRI 治疗的反应。本研究的目的是确定基线神经质和伤害避免评分是否与 SSRI 治疗后攻击性降低（通过公开攻击量表修订版 [OAS-M] 攻击性评分进行测量）相关。参加氟西汀随机、安慰剂对照临床试验的参与者在进入治疗试验之前完成了艾森克人格问卷（n= 57）和三维人格问卷（n= 38）。多元回归分析（考虑基线 OAS-M 攻击性得分）显示，治疗前艾森克人格问卷神经质和三维人格问卷伤害回避独立且独特地预测了氟西汀治疗组（而非安慰剂）治疗组终点时的 OAS-M 攻击性得分。这些初步研究结果首次来自安慰剂对照临床试验，表明神经质和避免伤害等气质因素可以部分解释在 SSRI 治疗的冲动攻击个体中观察到的治疗反应的变异性，并促进未来的前瞻性研究检查人格维度作为临床试验结果的预测因素。
Although selective serotonin reuptake inhibitors (SSRI) are generally effective in reducing impulsive aggression in individuals with intermittent explosive disorder, a large proportion of intermittent explosive disorder patients fail to achieve full remission despite adequate dosage and duration of treatment. Temperament, specifically those associated with negative emotionality (neuroticism, harm avoidance) may predict response to SSRI treatment. The objective of this study was to determine whether baseline neuroticism and harm avoidance scores would be associated with reduced aggression (as measured by the Overt Aggression Scale-Modified [OAS-M] aggression scores) after SSRI treatment. Participants participating in a randomized, placebo-controlled clinical trial of fluoxetine completed the Eysenck Personality Questionnaire (n= 57) and the Tridimensional Personality Questionnaire (n= 38) before entering the treatment trial. Multiple regression analyses (accounting for baseline OAS-M aggression scores) revealed that pretreatment eysenck personality questionnaire neuroticism and tridimensional personality questionnaire harm avoidance independently and uniquely predicted OAS-M aggression scores at endpoint in the fluoxetine, but not placebo, treated group. These preliminary findings are the first from a placebo-controlled clinical trial to suggest that temperamental factors such as neuroticism and harm avoidance can partly explain the observed variability in treatment response in SSRI treated individuals with impulsive aggression and prompt future prospective studies examining personality dimensions as predictors of outcomes in clinical trials.